Abstract The American Society of Regional Anesthesia and Pain Medicine (ASRA) 2012
survey of meeting attendees showed that existing ASRA anticoagulation guidelines for …

Background Chronic kidney disease (CKD) is a major global public health problem, being
closely connected to cardiovascular disease. CKD involves an elevated thromboembolic risk …

Background—Dabigatran 150 and 110 mg twice a day and warfarin are effective for stroke
prevention in atrial fibrillation. The purpose of this study was to compare their risks of …

This open‐label study evaluated apixaban pharmacokinetics, pharmacodynamics, and
safety in subjects with mild, moderate, or severe renal impairment and in healthy subjects …

There is an increasing awareness about the risks of arterial and venous thromboembolism
(TE) in hospital patients and general public which has led to consideration of thrombosis …

Importance Conflicting evidence exists regarding the association between warfarin
treatment, death, and ischemic stroke incidence in patients with advanced chronic kidney …

Oral anticoagulants are commonly used drugs in patients with CKD and patients with ESKD
to treat atrial fibrillation to reduce stroke and systemic embolism. Some of these drugs are …

Novel oral anticoagulants that directly inhibit thrombin (dabigatran) or factor Xa
(rivaroxaban, apixaban) are currently available for prevention of venous thromboembolism …

Background: Both atrial fibrillation and venous thromboembolism (VTE) are highly prevalent
among patients with chronic kidney disease (CKD). Until recently, warfarin was the most …

Warfarin dosing algorithms adjust for race, assigning a fixed effect size to each predictor,
thereby attenuating the differential effect by race. Attenuation likely occurs in both race …